Bharat Biotech manufactured Covaxin had successfully completed the animal trials on Friday. Covaxin is one of the leading inactive vaccines for the vaccine race in India.
The animal trails of Bharat Biotech International Limited’s Covid-19 vaccine candidate, Covaxin, has been successfully completed. Results regarding the test of the shots declared it as “remarkable immunogenicity and protective efficacy” in the Phase I clinical trials in India, Bharat Biotech claimed.
Covaxin, which was developed by the Indian Council of Medical Research (ICMR) and Bharat Biotech, is actively being tested across 12 institutes in the country.The Hyderabad-based firm said the data collected from the study on primates substantiate the immunogenicity of the vaccine candidate.
On Friday the Hyderabad based firm tweeted, “Bharat Biotech proudly announces the animal study results of COVAXIN – These results demonstrate the protective efficacy in a live viral challenge model.”
Bharat Biotech said in a release that it had developed and assessed the protective efficacy and immunogenicity of an inactivated Sar-CoV-2 vaccine (BBV152) or Covaxin in rhesus macaques. Twenty of the macaques were segregated into four groups of five animals each.
The results from the Covaxin animal trials.
The company further went on to assert, “One group was administered a placebo while three groups were immunised with three different vaccine candidates at 0 and 14 days. All the macaques were challenged with SARS-CoV-2 14 days after the second dose.
The protective response was observed with increasing SARS-CoV-2 specific IgG and neutralising antibody titres from third week post-immunisation.”
They also mentioned that a clearnace of the virus was seen from “bronchoalveolar lavage fluid, nasal swab, throat swab, and lung tissues in the 7 days post-infection vaccinated groups.
“No evidence of pneumonia was observed by histopathological examination in vaccinated groups, unlike the placebo group which showed features of interstitial pneumonia and localisation of viral antigen in the alveolar epithelium and macrophages by immunohistochemistry.
To summarize, the vaccine candidate was found to generate robust immune responses. Thus, preventing infection and disease in the primates upon high amounts of exposure to live SARS-CoV-2 virus.” Bharat Biotech concluded.
Bharat Biotech was granted approval from the Central Drugs Standard Control Organisation to conduct the Phase-II trials earlier this month. They had declared in June that they successfully developed Covaxin in collaboration with ICMR and the National Institute of Virology (NIV).
The SARS-CoV-2 strain was isolated at NIV, Pune and was then carefully transported to Bharat Biotech. The currently inactive vaccine candidate has been developed and manufactured in Bharat Biotech’s top notch containment center in Genome Valley, Hyderabad. (Source: HT)